You are here

Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Hospital in Debica - Zespo Opieki Zdrowotnej w Debicy
Debica, , 33-200 Poland
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tick-borne Encephalitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-67 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Male and female subjects will be eligible for participation in this study if:

- they understand the nature of the study, agree to its provisions and provide written
informed consent;

- they received the third vaccination with FSME-IMMUN 0.5ml during the course of Baxter
Study 213;

- blood was drawn before and after their third vaccination during the course of Baxter
Study 213;

- they showed an ELISA-concentration > 126 VIE U/ml and / or a NT-titer >= 1:10 after
the third vaccination in Baxter Study 213;

- they agree to keep a Subject Diary.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Subjects will be excluded from participation in this study if they:

- received any TBE vaccination since their third vaccination with FSME-IMMUN 0.5ml;

- received a vaccination against yellow fever and / or Japanese B-encephalitis since
their third vaccination with FSME-IMMUN 0.5ml;

- are known to be HIV positive (a special HIV test is not required for the purpose of
the study) since their third vaccination with FSME-IMMUN 0.5ml;

- have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week
or equivalent level of other alcoholic beverages);

- have received a blood transfusion or immunoglobulins within one month to the first and
second blood draw;

- have participated in another Baxter vaccine study within the last six months (with the
exception of follow-up studies).

Subjects will not be eligible for booster vaccination if:

- they do not meet the inclusion/exclusion criteria;

- they are not clinically healthy, (i.e. the physician would have reservations
vaccinating with FSME-IMMUN 0.5ml outside the scope of a clinical trial);

- they suffer from a disease (e.g. autoimmune disease) or are undergoing a form of
treatment (e.g. systemic corticosteroids) that can be expected to influence
immunological functions;

- they have donated blood or plasma within one month to the booster vaccination;

- female of childbearing potential are pregnant or breastfeeding before the booster
vaccination (positive pregnancy test result at the medical examination before the
booster vaccination);

- they have shown an allergic reaction to one of the components of the vaccine since
their third vaccination in Baxter Study 213;

- they are simultaneously participating in another clinical trial including
administration of an investigational product within six weeks prior to the booster
vaccination until the end of the study.

Subjects who meet the inclusion/exclusion criteria, but have a febrile illness (body
temperature >= 38.0°C, measured orally) at the scheduled time of vaccination, will not be
vaccinated until their body temperature returns to normal.

Subjects who have received any vaccination within two weeks prior to the booster
vaccination will not be vaccinated until an interval of two weeks has passed.

If subjects have received antipyretics within 4 hours prior to the intended TBE
vaccination, the vaccination should be performed at a later time.

NCT00161785
Pfizer
Completed
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Tick-borne Encephalitis
NCT00161889
All Genders
6+
Years
Multiple Sites
Tick-Borne Encephalitis
NCT00161967
All Genders
3+
Years
Multiple Sites
Tick-borne Encephalitis
NCT00161876
All Genders
16+
Years
Multiple Sites
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
Not Provided

The purpose of this study is to assess:

  • TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT).
  • TBE antibody response to a booster vaccination with FSME-IMMUN 0.5ml, by means of ELISA and NT.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Tick-borne Encephalitis
Biological: FSME-IMMUN 0.5ml
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
340
July 2005
Not Provided

Inclusion Criteria:

Male and female subjects will be eligible for participation in this study if:

  • they understand the nature of the study, agree to its provisions and provide written informed consent;
  • they received the third vaccination with FSME-IMMUN 0.5ml during the course of Baxter Study 213;
  • blood was drawn before and after their third vaccination during the course of Baxter Study 213;
  • they showed an ELISA-concentration > 126 VIE U/ml and / or a NT-titer >= 1:10 after the third vaccination in Baxter Study 213;
  • they agree to keep a Subject Diary.

Exclusion Criteria:

Subjects will be excluded from participation in this study if they:

  • received any TBE vaccination since their third vaccination with FSME-IMMUN 0.5ml;
  • received a vaccination against yellow fever and / or Japanese B-encephalitis since their third vaccination with FSME-IMMUN 0.5ml;
  • are known to be HIV positive (a special HIV test is not required for the purpose of the study) since their third vaccination with FSME-IMMUN 0.5ml;
  • have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages);
  • have received a blood transfusion or immunoglobulins within one month to the first and second blood draw;
  • have participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies).

Subjects will not be eligible for booster vaccination if:

  • they do not meet the inclusion/exclusion criteria;
  • they are not clinically healthy, (i.e. the physician would have reservations vaccinating with FSME-IMMUN 0.5ml outside the scope of a clinical trial);
  • they suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
  • they have donated blood or plasma within one month to the booster vaccination;
  • female of childbearing potential are pregnant or breastfeeding before the booster vaccination (positive pregnancy test result at the medical examination before the booster vaccination);
  • they have shown an allergic reaction to one of the components of the vaccine since their third vaccination in Baxter Study 213;
  • they are simultaneously participating in another clinical trial including administration of an investigational product within six weeks prior to the booster vaccination until the end of the study.

Subjects who meet the inclusion/exclusion criteria, but have a febrile illness (body temperature >= 38.0°C, measured orally) at the scheduled time of vaccination, will not be vaccinated until their body temperature returns to normal.

Subjects who have received any vaccination within two weeks prior to the booster vaccination will not be vaccinated until an interval of two weeks has passed.

If subjects have received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time.

Sexes Eligible for Study: All
18 Years to 67 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Poland
 
 
NCT00161785
223
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Principal Investigator: Ryszard Konior, MD Szpital Jana Pawla II Oddzial Neuroinfekcji, Krakow, Poland
Pfizer
May 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now